Company Interview Excerpt HANS DIETER RÖSSLER - CURASAN AG (549453.F) Full article published: 4/10/2002     For Subscribers Get this article online now! Order just this article Get Financial Filings and Annual Reports for Companies featured on TWST from EasyReports.net TWST: Could we begin with an overview of curasan's history, products and core markets? Mr. Roessler: curasan is a major player in the medical markets of regenerative biomedicine, including generics for anesthesia. We are located in the Rhine-main region, next to Frankfurt International Airport in Germany, which is an area that offers excellent infrastructure for our logistic interests. When I founded curasan in 1988, we started as a gatekeeper for marketing pharmaceuticals and medical devices. The core business consisted of blood plasma and local anesthetics, but over the years the product range was systematically expanded. A particular highlight in the company's development was the licensing of Cerasorb® at the end of 1997 and one year later clinical studies were initiated that led to excellent results in 1999. The millennium brought further changes as Cerasorb® received the innovation prize 2000 and the curasan Group converted from a private limited company into a public stock corporation. In 2001 we acquired two German companies, Titanium Innovations GmbH, including Ti-system that contains titanium membranes, titanium pins and a fixation system, and Pro-tec Medizinische Produkte GmbH. The latter produces the Hi-tech biomaterial Stypro®. This is a haemostyptic product that promotes wound healing and is available in different shapes and sizes. Today, curasan offers a wide range of pharmaceuticals, medical devices, biomaterials and biologicals. Our target groups are primarily surgeons and anesthetists in hospitals as well as specialists, such as orthopedic surgeons, pharmacologists and plastic surgeons. TWST: In percentage terms, can you break down the revenues that curasan derives from each of these areas? Mr. Roessler: In 2001 we reached approximately 12.5 million Euros in sales turnover, 55% of which was derived from pharmaceuticals and 45% from biomaterials/biologicals. The estimate for this year is an increase of 30% in sales turnover, which will lead to approximately 15.6 million Euros. Tickers included in this excerpt: 549453.F Have TWST notes emailed to you free: Email address: For more information call (212) 952 7400. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.

Why TWST? Money Managers: Thousands of easy-to-read verbatim CEO interviews Must-have backgrounder before meeting with management Analyst interviews offer discurse complement to published research Roundtables 2-6 analysts discuss sector from multi-broker perspective Fellow money managers discuss investment strategy and holdings. Company Research: Peer company research Strategic planning and partnership information Find out what Wall Street is saying about your company's sector and its competitors Tool for sales and marketing teams to learn customer needs Business Schools: Unique tool for investment clubs Background for finance, securities analysis and strategic planning classes Placement resource for researching potential employers Company research Market intelligence Consultants, Bankers & Corporate Advisors: Quick background study on all major business sectors Learn about potential client needs Research tool for serving current clients Subscribe Now